Answers are grounded in this paper and cite their sources.
Dendritic cells (DCs) are specialized antigen-presenting cells (APCs) that have an unequaled capacity to initiate primary immune responses, including tolerogenic responses. Because of the importance of DCs in the induction and control of immunity, an understanding of their biology is central to the development of potent immunotherapies for cancer, chronic infections, autoimmune disease, and induction of transplantation tolerance. This review discusses recent advances in DC research and the application of this knowledge toward new strategies for the clinical manipulation of DCs for cancer immunotherapy.
No takes yet. Share an insight, caveat, or question.
O’Neill et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: